Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders

Expert Opinion on Drug Safety

Volumn 17, Issue 2, 2018, Pages 197-205

  Pompili, Maurizio ^a   Verzura, Claudio ^b   Trovini, Giada ^b   Buscajoni, Andrea ^b   Falcone, Giulia ^b   Naim, Stefano ^b   Nardella, Adele ^b   Sorice, Serena ^b   Baldessarini, Ross J ^c   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Bipolar; depression; efficacy; lurasidone; safety; schizophrenia; tolerability

Indexed keywords

LITHIUM; LURASIDONE; VALPROIC ACID; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY WEIGHT CHANGE; BRADYKINESIA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; DYSTONIC DISORDER; ECG ABNORMALITY; GLUCOSE METABOLISM; HUMAN; HYPERPROLACTINEMIA; LIPID METABOLISM; LONG TERM CARE; MAJOR AFFECTIVE DISORDER; MANIA; META ANALYSIS; MOOD DISORDER; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; DOSE RESPONSE; PATHOPHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LURASIDONE HYDROCHLORIDE; MOOD DISORDERS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 85029908541     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1379989     Document Type: Article

References (42)

1. Baldessarini RJ., Chemotherapy in Psychiatry. third ed. New York: Springer Press; 2013.
2. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol ExpTher. 2010;334(1):171–181.
3. Tarazi FI, Riva MA., Preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Exp Opin Drug Discov. 2013;8(1):1297–1307.
4. Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: systematic review of the published literature. Clin Pharmacokinetics. 2017;56(5):493–503.
5. Potkin SG, Kimura T, Guarino J. Six-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–331.
6. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–967.
7. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: six-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–677.
8. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: six-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519–530.
9. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–836.
10. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 and 160 mg/day in the treatment of schizophrenia: randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Res. 2013;145(1–3):101–109.
11. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: 12-month, double-blind, noninferiority study. Schizophrenia Res. 2013;147(1):95–102.
12. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: randomized, six-week, open-label study. J Clin Psychiatry. 2013;74(2):170–179.
13. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507–515.
14. Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: 6-month, open-label, extension study. CNS Spectrums. 2014;19(4):330–339.
15. Correll CU, Cucchiaro J, Silva R, et al. Long-term safety and effectiveness of lurasidone in schizophrenia: 22-month, open-label extension study. CNS Spectrums. 2016;21(5):393–402.
16. Tandon R, Cucchiaro J, Phillips D, et al. Double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30(1):69–77.
17. Avila CC, Cabello M, Cieza A, et al. Functioning and disability in bipolar disorders: systematic review of literature using the ICF as a reference. Bipolar Disord. 2010;12(5):473–482.
18. Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234–1246.
19. Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–535.
20. Goodwin G. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
21. Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143–157.
22. Grunze H, Vieta E, Goodwin GM, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.
23. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
24. Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and major depressive disorders. J Affect Disord. 2015;178(6):71–78.
25. Vázquez GH, Holtzman JN, Tondo L, et al. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183(9):258–262.
26. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–1262.
27. Vázquez GH, Tondo L, Undurraga J, et al. Overview of antidepressant treatment in bipolar depression: critical commentary. Intl J Neuropsychopharmacol. 2013;16(7):1673–1685.
28. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: review of its use in bipolar disorder. Drugs. 2003;63(19):2029–2050.
29. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–529.
30. Selle V, Schalkwijk S, Vázquez GH, et al. Treatments for acute bipolar depression: meta-analysis of placebo-controlled monotherapy trials of lithium, anticonvulsants, and antipsychotics. Pharmacopsychiatry. 2013;47(2):43–52.
31. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
32. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177.
33. Suppes T, Kroger H, Pikalov A, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: placebo-controlled trial utilizing prospective and retrospective enrollment cohorts. J Psychiatr Res. 2016;78(7):86–93.
34. Fornaro M, De Berardis D, Perna G, et al. Lurasidone in the treatment of bipolar depression: systematic review. Biomed Res Int. 2017;2017(5:3084859):1–17.
35. McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(4):398–405.
36. Sajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post-hoc analysis of two double-blind, placebo-controlled studies. J Clin Psychiatry. 2016;77(10):e1324–e1331.
37. Ketter TA, Sarma K, Silva R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: 24-week open-label extension study. Depress Anxiety. 2016;33(5):424–434.
38. Calabrese JR, Keck PE, Jr, MacFadden W, et al. Randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
39. Corya SA, Perlis RH, Keck PE, et al. 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67(5):798–806.
40. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder With mixed features: randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–407.
41. Meyer JM, Mao Y, Pikalov A, et al. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(6):342–350.
42. Vázquez CH, Lolich M, Cabrera C, et al. Mixed symptoms in mood disorders: systematic review. J Affect Disord. 2018;225(1):756–760.